



# Managing Patients with Rheumatic Disorders in Primary Care



## REFERENCES

- Abeles AM, Abeles M. The clinical utility of a positive antinuclear antibody test result. *Am J Med.* 2013;126(4):342-348. doi:10.1016/j.amjmed.2012.09.014
- Akpek EK, Bunya VY, Saldanha IJ. Sjögren's syndrome: More than just dry eye. *Cornea.* 2019;38(5):658-661. doi:10.1097/ICO.0000000000001865
- Almaani S, Meara A, Rovin BH. Update on lupus nephritis. *Clin J Am Soc Nephrol.* 2017;12(5):825-835. doi:10.2215/CJN.05780616
- Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. *Ann Rheum Dis.* 2006;65(7):845-851. doi:10.1136/ard.2006.051391
- Barut K, Adrovic A, Şahin S, Kasapçopur Ö. Juvenile idiopathic arthritis. *Balkan Med J.* 2017;34(2):90-101. doi:10.4274/balkanmedj.2017.0111
- Benveniste O, Musset L. (2020). Making the diagnosis of myositis: Laboratory testing in myositis. In: Aggarwal R, Oddis CV. (eds) *Managing Myositis. A Practical Guide.* [https://doi.org/10.1007/978-3-030-15820-0\\_17](https://doi.org/10.1007/978-3-030-15820-0_17)
- Braun J, Blanco R, Marzo-Ortega H, et al. Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis. *Arthritis Res Ther.* 2023;25(1):80. Published 2023 May 16. doi:10.1186/s13075-023-03051-5
- Brunner HI, Abud-Mendoza C, Mori M, et al. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. *RMD Open.* 2021;7(3):e001747. doi:10.1136/rmdopen-2021-001747
- Casey KA, Guo X, Smith MA, et al. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE [published correction appears in *Lupus Sci Med.* 2018 Dec 22;5(1):e000286corr1]. *Lupus Sci Med.* 2018;5(1):e000286. Published 2018 Nov 22. doi:10.1136/lupus-2018-000286
- Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. *Clin Med (Lond).* 2017;17(1):65-70. doi:10.7861/clinmedicine.17-1-65
- De Carolis S, Garufi C, Garufi E, et al. Autoimmune congenital heart block: A review of biomarkers and management of pregnancy. *Front Pediatr.* 2020;8:607515. Published 2020 Dec 22. doi:10.3389/fped.2020.607515
- De Filippo C, Di Paola M, Giani T, Tirelli F, Cimaz R. Gut microbiota in children and altered profiles in juvenile idiopathic arthritis. *J Autoimmun.* 2019;98:1-12. doi:10.1016/j.jaut.2019.01.001
- Deodhar A, Blanco R, Dokoupilová E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: Primary results of a randomized, placebo-controlled phase III study. *Arthritis Rheumatol.* 2021;73(1):110-120. doi:10.1002/art.41477
- Deodhar A, Gensler LS, Kay J, et al. A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. *Arthritis Rheumatol.* 2019;71(7):1101-1111. doi:10.1002/art.40866
- Deodhar A, Van den Bosch F, Poddubnyy D, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2022;400(10349):369-379. doi:10.1016/S0140-6736(22)01212-0
- Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. *Lancet.* 2020;395(10217):53-64. doi:10.1016/S0140-6736(19)32971-X
- Dydyk AM, Forro SD, Hanna A. Sacroiliac joint injury. In: *StatPearls. Treasure Island (FL): StatPearls Publishing; January 15, 2023.*

# Managing Patients with Rheumatic Disorders in Primary Care



- Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. *Arthritis Rheum.* 2011;63(12):3918-3930. doi:10.1002/art.30613
- Furie R, Morand EF, Askanase AD, et al. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. *Lupus.* 2021;30(8):1254-1263. doi:10.1177/09612033211014267
- Gerber MA, Zemel LS, Shapiro ED. Lyme arthritis in children: clinical epidemiology and long-term outcomes. *Pediatrics.* 1998;102(4 Pt 1):905-908. doi:10.1542/peds.102.4.905
- Harrold LR, Shan Y, Rebello S, et al. Prevalence of Sjögren's syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry. *Clin Rheumatol.* 2020;39(6):1899-1905. doi:10.1007/s10067-020-05004-8
- Infantino M, Nagy E, Bizzaro N, Fischer K, Bossuyt X, Damoiseaux J. Anti-dsDNA antibodies in the classification criteria of systemic lupus erythematosus. *J Transl Autoimmun.* 2021;5:100139. Published 2021 Dec 28. doi:10.1016/j.jtauto.2021.100139
- Kalunian KC, Furie R, Morand EF, et al. A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. *Arthritis Rheumatol.* 2023;75(2):253-265. doi:10.1002/art.42392
- Kate A, Shanbhag SS, Donthineni PR, Amescua G, Quinones VLP, Basu S. Role of topical and systemic immunosuppression in aqueous-deficient dry eye disease. *Indian J Ophthalmol.* 2023;71(4):1176-1189. doi:10.4103/IJO.IJO\_2818\_22
- Kumar Y, Bhatia A, Minz RW. Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited. *Diagn Pathol.* 2009;4:1. doi:10.1186/1746-1596-4-1
- Liang Y, Leng RX, Pan HF, Ye DQ. Associated variables of myositis in systemic lupus erythematosus: A cross-sectional study. *Med Sci Monit.* 2017;23:2543-2549. Published 2017 May 26. doi:10.12659/msm.902016
- Lochhead RB, Strle K, Arvikar SL, Weis JJ, Steere AC. Lyme arthritis: linking infection, inflammation and autoimmunity. *Nat Rev Rheumatol.* 2021;17(8):449-461. doi:10.1038/s41584-021-00648-5
- Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. *Lancet.* 2020;396(10264):1745-1757. doi:10.1016/S0140-6736(20)32234-0
- Mammen AL. Autoimmune myopathies. *Continuum (Minneapolis, Minn).* 2016;22(6, Muscle and Neuromuscular Junction Disorders):1852-1870. doi:10.1212/01.CON.0000511070.50715.ab
- McAdams DeMarco MA, Maynard JW, Baer AN, et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. *Arthritis Rheum.* 2012;64(1):121-129. doi:10.1002/art.33315
- Medjedovic E, Medjedovic S, Deljo D, Sukalo A. IMPACT OF FLUORIDE ON DENTAL HEALTH QUALITY. *Mater Sociomed.* 2015;27(6):395-398. doi:10.5455/msm.2015.27.395-398
- Michaelov E, McKenna C, Ibrahim P, Nayeni M, Dang A, Mather R. Sjögren's syndrome associated dry eye: Impact on daily living and adherence to therapy. *J Clin Med.* 2022;11(10):2809. Published 2022 May 16. doi:10.3390/jcm11102809
- Morand EF, Abreu G, Furie RA, Golder V, Tummala R. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. *Ann Rheum Dis.* 2023;82(5):639-645. doi:10.1136/ard-2022-222748
- Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. *N Engl J Med.* 2020;382(3):211-221. doi:10.1056/NEJMoa1912196

# Managing Patients with Rheumatic Disorders in Primary Care



Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet*. 2011;377(9767):721-731. doi:10.1016/S0140-6736(10)61354-2

O'Dell JR, Brophy MT, Pillinger MH, et al. Comparative effectiveness of allopurinol and febuxostat in gout management. *NEJM Evid*. 2022;1(3):10.1056/evidoa2100028. doi:10.1056/evidoa2100028

Ostergaard M, Lambert RG. Imaging in ankylosing spondylitis. *Ther Adv Musculoskelet Dis*. 2012;4(4):301-311. doi:10.1177/1759720X11436240

Pillinger MH, Mandell BF. Therapeutic approaches in the treatment of gout. *Semin Arthritis Rheum*. 50: S24-30, 2020. doi:[10.1016/j.semarthrit.2020.04.010](https://doi.org/10.1016/j.semarthrit.2020.04.010)

PLAQUENIL® (hydroxychloroquine sulfate) tablets. Prescribing information. Sanofi-Aventis U.S. LLC. Accessed July 26, 2023. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2007/009768s041lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009768s041lbl.pdf)

Riccio A, Tarantino G. Hepatitis C virus-related arthritis and rheumatoid arthritis: could they be different aspects of the same disease?. *Int J Immunopathol Pharmacol*. 2012;25(1):293-296. doi:10.1177/039463201202500134

Rosenbaum JT, Bodaghi B, Couto C, et al. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review. *Semin Arthritis Rheum*. 2019;49(3):438-445. doi:10.1016/j.semarthrit.2019.06.004

Sivera F, Núñez-Monje V, Campos-Fernández C, et al. Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum. *Front Med (Lausanne)*. 2023;10:1156557. Published 2023 May 11. doi:10.3389/fmed.2023.1156557

Slater CA, Davis RB, Shmerling RH. Antinuclear antibody testing. A study of clinical utility. *Arch Intern Med*. 1996;156(13):1421-1425.

Stanton M, Tiwari V. Polyarteritis nodosa. In: *StatPearls. Treasure Island (FL): StatPearls Publishing; February 22, 2023.*

Su N, Marek CL, Ching V, Grushka M. Caries prevention for patients with dry mouth. *J Can Dent Assoc*. 2011;77:b85.